Latest News and Press Releases

BYOOVIZ™ is the first FDA approved ophthalmology biosimilar BYOOVIZ, priced 40% lower than LUCENTIS®, provides an equally effective and more affordable treatment option to patients suffering from...

Samsung Bioepis and Biogen to present one abstract and one poster at EULAR 2022 on adalimumab biosimilar, SB5 including Phase 1 study of a new SB5 formulation and a pan-European real-world study,...

INCHEON, Korea and TORONTO, March 10, 2022 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Canada Inc. today announced that Health Canada has approved BYOOVIZ™ – a biosimilar referencing...

Holds a virtual ceremonial event for the first time to mark the anniversary with its global employees Pledges to keep innovating access to biologic medicines worldwide INCHEON, Korea, Feb. 28, 2022...

150mg and 440mg vial of ONTRUZANT® are now approved in CanadaONTRUZANT® becomes Samsung Bioepis’ fifth biosimilar to be approved in Canada in just six years INCHEON, Korea, Feb. 02, 2022 (GLOBE...

Outlines the company’s Environment, Social and Governance (ESG) performance and commitment to becoming a socially responsible and sustainable companyAppoints dedicated ESG team to explore and...

Phase 1 study demonstrated pharmacokinetics (PK) equivalence and comparable pharmacodynamic (PD), safety, immunogenicity profiles between SB12 and reference eculizumab INCHEON, Korea, Dec. 11,...

Five-year follow-up results reconfirm comparable long-term efficacy of SB3 (ONTRUZANT®, trastuzumab-dttb) versus Herceptin® through additional analysis with a larger group of patients with...

Healthcare professionals can benefit from more education to address knowledge gaps about the FDA’s robust evaluation, review, and approval standards for biosimilarsDo prescribers and patients benefit...

BYOOVIZ™ becomes the first ophthalmology biosimilar to gain FDA approval in the United States  INCHEON, Korea and CAMBRIDGE, Mass., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and...